Dr. Whelan Provides a MA.20 Trial Result Summary

Timothy J. Whelan, BM, BCh
Published: Thursday, Jul 14, 2011



Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, explains that the results from his NCIC-CTG MA.20 intergroup phase III trial demonstrated that women with breast cancer that have 1-3 positives nodes after breast conserving surgery, usually receiving whole breast irradiation, will benefit from the addition of regional radiation to their treatment.


Lead study investigator Timothy J. Whelan, BM, BCh, professor of Oncology and the division head of Radiation Oncology at McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario, explains that the results from his NCIC-CTG MA.20 intergroup phase III trial demonstrated that women with breast cancer that have 1-3 positives nodes after breast conserving surgery, usually receiving whole breast irradiation, will benefit from the addition of regional radiation to their treatment.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x